GlassScriptPhysician profile
Benjamin Leon Musher
NPI 1922160852
$81,359.23
in general payments reported to CMS, 2019-2025
24 companies · $257 in 2025
The $257 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $50K · 2020: $5,409 · 2021: $9,456 · 2022: $13K · 2023: $2,762 · 2024: $313 · 2025: $257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,600 · Food and Beverage: $731.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,600.00 |
| Food and Beverage | $730.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $58,310.10 | 2019-2025 | Onivyde |
| Exelixis INC. | $12,045.56 | 2019-2025 | Cabometyx |
| Celgene Corporation | $7,399.96 | 2019 | |
| Sirtex Medical INC | $2,744.05 | 2023 | Sir-Spheres Microspheres |
| Regeneron Healthcare Solutions, INC. | $130.58 | 2022 | |
| Aveo Pharmaceuticals, INC. | $118.69 | 2022 | |
| Jazz Pharmaceuticals INC. | $103.03 | 2024 | |
| Amgen INC. | $85.39 | 2021-2022 | |
| Lilly USA, LLC | $49.93 | 2019-2022 | |
| Abbvie INC. | $49.84 | 2020-2022 | |
| Array Biopharma INC | $49.19 | 2024 | Braftovi, Mektovi, Tukysa |
| Astrazeneca Pharmaceuticals LP | $40.30 | 2019-2023 | Imjudo |
| Johnson & Johnson Health Care Systems INC. | $39.90 | 2025 | Darzalex |
| Novartis Pharmaceuticals Corporation | $36.03 | 2022 | |
| Genentech USA, INC. | $25.38 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $24.92 | 2022 | |
| Incyte Corporation | $24.04 | 2022 | |
| Eisai INC. | $23.61 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $22.82 | 2025 | Opdualag |
| Janssen Biotech, INC. | $20.68 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.23 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Musher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.